Microglia stimulated by VHB937 turned down expression of SPP1, soluble CSF1R, and CCL3. Based on these data, Novartis took VHB937 into people. In Vienna, Judit Sovago presented interim findings from a ...

The company has an inhibitor of CSF1R – vimseltinib – which is due to start a phase 1/2 trial in tenoysynovial giant cell tumour (TGCT) before the end of the year. Other early-stage programmes ...

603259.SS WuXi AppTec Co., Ltd.

Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The tumour microenvironment (TME) in PDA is highly dynamic and has been found to promote tumour progression, ...